{"id":477003,"date":"2021-04-15T09:03:58","date_gmt":"2021-04-15T13:03:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/"},"modified":"2021-04-15T09:03:58","modified_gmt":"2021-04-15T13:03:58","slug":"seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/","title":{"rendered":"Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, April 15, 2021<\/span> \/PRNewswire\/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Neuroscience Conference, April 28-29, 2021<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Seelos
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th<\/span> at 11:00am ET<\/span>.\u00a0 <\/p>\n

The B. Riley Securities’ Neuroscience Conference will cover key topics across neurodegeneration, neuropsychiatry, and mental health disease areas, with both public and private healthcare companies. For more information about the conference: https:\/\/brileyfin.com\/events<\/a><\/p>\n

\n About Seelos Therapeutics <\/b>
\n \n <\/p>\n

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s disease, other psychiatric and movement disorders plus orphan diseases.<\/p>\n

For more information, please visit our website: http:\/\/seelostherapeutics.com<\/a>, the content of which is not incorporated herein by reference.<\/p>\n

Contact Information: <\/p>\n

\n Anthony Marciano<\/span>
\n
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY<\/span> 10022
(646) 293-2136
anthony.marciano@seelostx.com<\/a> \u00a0
https:\/\/seelostherapeutics.com\/<\/a> \u00a0
https:\/\/twitter.com\/seelostx<\/a> \u00a0
https:\/\/www.linkedin.com\/company\/seelos<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference-301269110.html<\/a><\/p>\n

SOURCE Seelos Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, April 15, 2021 \/PRNewswire\/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Neuroscience Conference, April 28-29, 2021. Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET.\u00a0 The B. Riley Securities’ Neuroscience Conference will cover key topics across neurodegeneration, neuropsychiatry, and mental health disease areas, with both public and private healthcare companies. For more information about the conference: https:\/\/brileyfin.com\/events About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs … <\/p>\n

Continue reading “Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-477003","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSeelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, April 15, 2021 \/PRNewswire\/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Neuroscience Conference, April 28-29, 2021. Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET.\u00a0 The B. Riley Securities’ Neuroscience Conference will cover key topics across neurodegeneration, neuropsychiatry, and mental health disease areas, with both public and private healthcare companies. For more information about the conference: https:\/\/brileyfin.com\/events About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs … Continue reading "Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T13:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference\",\"datePublished\":\"2021-04-15T13:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/\"},\"wordCount\":264,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/\",\"name\":\"Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"datePublished\":\"2021-04-15T13:03:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1244961\\\/Seelos_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/","og_locale":"en_US","og_type":"article","og_title":"Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference - Market Newsdesk","og_description":"PR Newswire NEW YORK, April 15, 2021 \/PRNewswire\/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the B. Riley Securities’ Neuroscience Conference, April 28-29, 2021. Raj Mehra, Ph.D., Chairman and CEO, will present on Wednesday, April 28th at 11:00am ET.\u00a0 The B. Riley Securities’ Neuroscience Conference will cover key topics across neurodegeneration, neuropsychiatry, and mental health disease areas, with both public and private healthcare companies. For more information about the conference: https:\/\/brileyfin.com\/events About Seelos Therapeutics Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs … Continue reading \"Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T13:03:58+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference","datePublished":"2021-04-15T13:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/"},"wordCount":264,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/","name":"Seelos Therapeutics to Participate in the B. Riley Securities' Neuroscience Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","datePublished":"2021-04-15T13:03:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1244961\/Seelos_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/seelos-therapeutics-to-participate-in-the-b-riley-securities-neuroscience-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Seelos Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=477003"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477003\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=477003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=477003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=477003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}